NCT03726021View on ClinicalTrials.gov

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

February 28, 2023

Conditions
Overall Survival
Interventions
DRUG

Irinotecan,Oxaliplatin, and S1

"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"

Trial Locations (1)

266042

Qingdao Central Hospital, Qingdao

All Listed Sponsors
lead

Qingdao Central Hospital

OTHER

NCT03726021 - Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter